Spectral Diagnostics Inc. (OTCMKTS:EDTXF) Short Interest Update

Spectral Diagnostics Inc. (OTCMKTS:EDTXF) saw a large decrease in short interest in the month of September. As of September 15th, there was short interest totaling 7,906 shares, a decrease of 39.6% from the August 31st total of 13,085 shares. Based on an average daily trading volume, of 14,380 shares, the days-to-cover ratio is currently 0.5 days. Approximately 0.0% of the shares of the company are short sold.

Spectral Diagnostics Price Performance

OTCMKTS EDTXF remained flat at $0.81 on Thursday. 2,600 shares of the company’s stock traded hands, compared to its average volume of 13,436. Spectral Diagnostics has a twelve month low of $0.65 and a twelve month high of $1.15. The stock’s fifty day moving average price is $0.93 and its 200-day moving average price is $0.97. The firm has a market cap of $239.37 million, a price-to-earnings ratio of -8.12 and a beta of 0.16.

Spectral Diagnostics Company Profile

Spectral Diagnostics, now known as Spectral Medical Inc, is a Canadian medical-device and biotechnology company focused on products for the diagnosis and treatment of sepsis and septic shock. The company’s work centers on identifying endotoxemia, a condition in which bacterial endotoxins enter the bloodstream and can contribute to severe systemic inflammation.

Spectral’s primary diagnostic product is the Endotoxin Activity Assay (EAA), a blood test designed to measure a patient’s endotoxin activity and help identify individuals who may be at increased risk of developing severe sepsis.